TISIDB

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus, nucleoplasm. Nucleus, nucleolus. Note=Translocates from the nucleoli to the nucleoplasm in presence of several stressors like ultraviolet irradiation and actinomycin-D. Predominantly detected in the nucleoli in non-mitotic cells. Predominantly detected in nucleoplasma in cells undergoing mitosis.
Domain	PF03715 Noc2p family
Function	Acts as an inhibitor of histone acetyltransferase activity; prevents acetylation of all core histones by the EP300/p300 histone acetyltransferase at p53/TP53-regulated target promoters in a histone deacetylases (HDAC)-independent manner. Acts as a transcription corepressor of p53/TP53- and TP63-mediated transactivation of the p21/CDKN1A promoter. Involved in the regulation of p53/TP53-dependent apoptosis. Associates together with TP63 isoform TA*-gamma to the p21/CDKN1A promoter.

> Gene Ontology [ TOP ]
Biological Process	GO:0001783 B cell apoptotic process GO:0002902 regulation of B cell apoptotic process GO:0002903 negative regulation of B cell apoptotic process GO:0006323 DNA packaging GO:0006333 chromatin assembly or disassembly GO:0006473 protein acetylation GO:0006475 internal protein amino acid acetylation GO:0009314 response to radiation GO:0009411 response to UV GO:0009416 response to light stimulus GO:0016570 histone modification GO:0016573 histone acetylation GO:0018205 peptidyl-lysine modification GO:0018393 internal peptidyl-lysine acetylation GO:0018394 peptidyl-lysine acetylation GO:0022613 ribonucleoprotein complex biogenesis GO:0031056 regulation of histone modification GO:0031057 negative regulation of histone modification GO:0031497 chromatin assembly GO:0032066 nucleolus to nucleoplasm transport GO:0034644 cellular response to UV GO:0035065 regulation of histone acetylation GO:0035067 negative regulation of histone acetylation GO:0042254 ribosome biogenesis GO:0042273 ribosomal large subunit biogenesis GO:0043543 protein acylation GO:0051169 nuclear transport GO:0070227 lymphocyte apoptotic process GO:0070228 regulation of lymphocyte apoptotic process GO:0070229 negative regulation of lymphocyte apoptotic process GO:0071103 DNA conformation change GO:0071214 cellular response to abiotic stimulus GO:0071478 cellular response to radiation GO:0071482 cellular response to light stimulus GO:0071887 leukocyte apoptotic process GO:0072331 signal transduction by p53 class mediator GO:0097193 intrinsic apoptotic signaling pathway GO:1901796 regulation of signal transduction by p53 class mediator GO:1901983 regulation of protein acetylation GO:1901984 negative regulation of protein acetylation GO:1902275 regulation of chromatin organization GO:1902532 negative regulation of intracellular signal transduction GO:1905268 negative regulation of chromatin organization GO:2000106 regulation of leukocyte apoptotic process GO:2000107 negative regulation of leukocyte apoptotic process GO:2000756 regulation of peptidyl-lysine acetylation GO:2000757 negative regulation of peptidyl-lysine acetylation GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001242 regulation of intrinsic apoptotic signaling pathway GO:2001243 negative regulation of intrinsic apoptotic signaling pathway
Molecular Function	GO:0003682 chromatin binding GO:0003714 transcription corepressor activity GO:0008134 transcription factor binding GO:0031491 nucleosome binding GO:0042393 histone binding GO:0070491 repressing transcription factor binding
Cellular Component	GO:0030684 preribosome GO:0030686 90S preribosome GO:0030687 preribosome, large subunit precursor GO:0030689 Noc complex GO:0030690 Noc1p-Noc2p complex GO:0030691 Noc2p-Noc3p complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation R-HSA-3700989: Transcriptional Regulation by TP53

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NOC2L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NOC2L and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
29673644	Squamous Cell Carcinoma	Promote immunity	When illuminating with NIR light, PIT can induce highly-selective cancer cell death while leaving most of tumor blood vessels unharmed, leading to an effect termed super-enhanced permeability and retention (SUPR), which can significantly improve the effectiveness of anti-cancer drug.
29670088	Metastatic Malignant Neoplasm	Promote immunity	A mechanical study reveals that NIR light-triggered antigen release and JQ1-mediated PD-L1 checkpoint blockade cumulatively contribute to the satisfied therapeutic effect.

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NOC2L in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NOC2L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.291	0.379
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.158	0.95
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.385	0.834
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.293	0.418
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.284	0.9
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.302	0.914
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.225	0.563
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.018	0.991
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.504	0.783
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.168	0.917
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.426	0.857
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.066	0.361

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NOC2L in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	4.8	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	22.2	0.12
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	50	50	0.109
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NOC2L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NOC2L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NOC2L. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NOC2L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NOC2L expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NOC2L and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NOC2L
Name	NOC2-like nucleolar associated transcriptional repressor
Aliases	DKFZP564C186; NET15; NIR; PPP1R112; novel INHAT repressor; protein phosphatase 1, regulatory subunit 12; nuc ......
Chromosomal Location	1p36.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NOC2L collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NOC2L